Methods for the treatment of recurrent glioblastoma (RGBM)
Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.
1. A method for treating recurrent glioblastoma multiforme (RGBM) in a patient in need thereof, the method consisting of:
(a) intravenously administering to a patient a plurality of extraneous antineoplastons consisting of about a 4:1 ratio of phenylacetate (PN) and phenylacetylglutaminate sodium (PG) at a dosage of from about 0.08 g/kg/day to about 0.6 g/kg/day; and
(b) administering to the patient a plurality of targeted agents consisting of pazopanib administered orally at a dose of from about 1 mg/kg/day to about 12 mg/kg/day,
dasatinib administered orally at a dose of from about 0.3 mg/kg/day to about 2.0 mg/kg/day,
everolimus administered orally at a dose of from about 0.03 mg/kg/day to about 0.15 mg/kg/day, and
bevacizumab administered intravenously every 1 to 3 weeks at a dose of from about 2 mg/kg/day to about 15 mg/kg/day.
2. The method of claim 1 , wherein the plurality of extraneous antineoplastons consists of about a 4:1 ratio of PN and PG in the following amounts:
from about 0.064 g/kg/day to about 0.48 g/kg/day PN and
from about 0.016 g/kg/day to about 0.12 g/kg/day PG.
3. The method of claim 1 , wherein the plurality of extraneous antineoplastons and the pazopanib, dasatinib, and everolimus are administered daily for at least 8 weeks and the bevacizumab is administered intravenously every 1 to 3 weeks for at least 8 weeks.
4. The method of claim 1 , wherein the patient failed to achieve an objective response as a result of at least one radiation treatment and/or at least chemotherapy treatment comprising temozolomide (TMZ) and/or bevacizumab (BVZ), prior to the administration of the plurality of extraneous antineoplastons and the plurality of targeted agents.
5. The method of claim 1 , wherein the patient has undergone a resection of a glioma prior to the administration of the plurality of extraneous antineoplastons and the plurality of targeted agents.
6. A method for treating recurrent glioblastoma multiforme (RGBM) in a patient in need thereof, the method consisting of concurrently administering to a patient:
(a) intravenously, a plurality of extraneous antineoplastons consisting of about a 4:1 ratio of phenylacetate (PN) and phenylacetylglutaminate sodium (PG) at a dosage of from about 0.08 g/kg/day to about 0.6 g/kg/day;
(b) orally, pazopanib at a dose of from about 1 mg/kg/day to about 12 mg/kg/day, dasatinib at a dose of from about 0.3 mg/kg/day to about 2.0 mg/kg/day, and everolimus at a dose of from about 0.03 mg/kg/day to about 0.15 mg/kg/day; and
(c) intravenously, bevacizumab every 1 to 3 weeks at a dose of from about 2 mg/kg/day to about 15 mg/kg/day.
7. The method of claim 6 , wherein the plurality of extraneous antineoplastons consists of about a 4:1 ratio of PN and PG in the following amounts:
from about 0.064 g/kg/day to about 0.48 g/kg/day PN; and
from about 0.016 g/kg/day to about 0.12 g/kg/day PG.
8. The method of claim 1 , wherein the about a 4:1 ratio of phenylacetate (PN) and phenylacetylglutaminate sodium (PG) is intravenously administered at a dosage of from about 0.2 g/kg/day to about 0.4 g/kg/day.
9. The method of claim 6 , wherein the about a 4:1 ratio of phenylacetate (PN) and phenylacetylglutaminate sodium (PG) is intravenously administered at a dosage of from about 0.2 g/kg/day to about 0.4 g/kg/day.